Want to Learn How To Take Advantage of Clinical Trials?

webinar patients rising logo

Join Patients Rising on May 14 at 1pm ET (10am PT) for an informative webinar on taking advantage of clinical trials.  Clinical trials are at the heart of all advances in medicine.  They lead to new innovations in preventing, detecting, and treating disease.  They allow researchers to test new treatments and new ways to use existing treatments.  Clinical trials determine if new treatments are safe and effective.

There are many reasons to participate in a clinical trial.  In this webinar, their panel will help you explore the benefits and risks and how clinical trials can fit into your healthcare plan.  They will explain why you should care about clinical trials, how they work, and potential risks.  They will answer your questions about clinical trials and point you to valuable resources to search for and learn more about clinical trials.

Please join Patients Rising on Tuesday, May 14 at 1pm ET (10am PT)!

Learn more and register here!

Have You Heard Of STARTRK2 Ignyta Clinical Trial?

Ignyta Clinical Trial

Lacuna Loft’s mission is bringing resources and support to young adult cancer survivors and caregivers.  Sometimes that means we run an awesome Writing Group and sometimes that means talking about the importance of clinical trials and other studies in which you can take part.

Ignyta is running a trial and bringing molecular testing to the forefront of cancer cures.  From Ignyta:

We’re writing to share information about the STARTRK-2 clinical trial (sponsored by Ignyta) that is currently recruiting patients across the country who have solid tumors harboring NTRKROS1, or ALK fusions.  Fusions are a certain type of DNA defect that have been reported to be oncogenic, meaning they could be a cause of your cancer.  By performing molecular testing on a piece of your tumor tissue, it may determine if your cancer has one of these fusions.

Ignyta can provide no-cost molecular testing to see if you may qualify for the trial.  In most cases, this test can be performed on a tumor sample that was previously obtained via biopsy and stored, avoiding the need for a new biopsy.

Eligible patients enrolled into the trial will receive a new investigational drug called Entrectinib.  Entrectinib has shown preliminary antitumor activity in many different types of cancers.  Click here to learn more about a recent update from our Phase 1 study.

Please speak with your doctor to determine if molecular testing is right for you.  You may also contact Ignyta at 1.844.STARTRK or via email at STARTRKtrials@ignyta.com to learn more about the trial and to find a participating study center near you.

Have you been molecularly tested?  Interested in other studies?  Check out more information we’ve shared recently here.

Stage IV Breast Or Prostate Cancer?

treatment access platform

Lacuna Loft is partnered with a company that is changing the landscape of how cancer patients access treatment options. The company was founded by a radiation oncologist and a pathologist, they have young adult cancer survivors on their team, and they help patients with Stage IV breast or prostate cancer identify their unique clinical trial options at top cancer centers in the United States. For a limited time, the company is offering this service at no cost to patients with Stage IV breast or prostate cancer in the Lacuna Loft community.

If you’re interested in learning more, please fill out this form and a member of their team will reach out to you to set up a time for a call where they will share more about the company and how they can help.

STARTRK2 Ignyta Clinical Trial is still recruiting!

ignyta clinical trial

Lacuna Loft believes strongly in helping young adult cancer patients have better access to clinical trials and studies since these young adults are grossly underrepresented.  Adolescent and young adult cancer patients haven’t experienced an increase in survival rates since the ’70s and researchers believe that clinical trial participation could help change this!  Clinical trials help find cures and we love sharing them with you.

Ignyta is running a trial and bringing molecular testing to the forefront of cancer cures.  From Ignyta:

We’re writing to share information about the STARTRK-2 clinical trial (sponsored by Ignyta) that is currently recruiting patients across the country who have solid tumors harboring NTRKROS1, or ALK fusions.  Fusions are a certain type of DNA defect that have been reported to be oncogenic, meaning they could be a cause of your cancer.  By performing molecular testing on a piece of your tumor tissue, it may determine if your cancer has one of these fusions.

Ignyta can provide no-cost molecular testing to see if you may qualify for the trial.  In most cases, this test can be performed on a tumor sample that was previously obtained via biopsy and stored, avoiding the need for a new biopsy.

Eligible patients enrolled into the trial will receive a new investigational drug called Entrectinib.  Entrectinib has shown preliminary antitumor activity in many different types of cancers.  Click here to learn more about a recent update from our Phase 1 study.

Please speak with your doctor to determine if molecular testing is right for you.  You may also contact Ignyta at 1.844.STARTRK or via email at STARTRKtrials@ignyta.com to learn more about the trial and to find a participating study center near you.

Interested in other studies?  Check out more information we’ve shared recently here.

STARTRK2 Ignyta Clinical Trial!

Ignyta clinical trial

Lacuna Loft believes strongly in helping young adult cancer patients have better access to clinical trials and studies.  Young Adult cancer patients are often underrepresented in clinical trials which is one of the facts researchers point to when citing that adolescent and young adult cancer patients haven’t experienced an increase in survival rates since the 70s, unlike both the younger and older cancer patient populations.  Clinical trials help find cures and we love sharing them with you.

We’ve shared about lots of different studies recently.  Check them out here if you haven’t already!

Today we’re talking about a trial that Igynta is running.  From Ignyta:

We’re writing to share information about the STARTRK-2 clinical trial (sponsored by Ignyta) that is currently recruiting patients across the country who have solid tumors harboring NTRK, ROS1, or ALK fusions.  Fusions are a certain type of DNA defect that have been reported to be oncogenic, meaning they could be a cause of your cancer.  By performing molecular testing on a piece of your tumor tissue, it may determine if your cancer has one of these fusions.

Ignyta can provide no-cost molecular testing to see if you may qualify for the trial.  In most cases, this test can be performed on a tumor sample that was previously obtained via biopsy and stored, avoiding the need for a new biopsy.

Eligible patients enrolled into the trial will receive a new investigational drug called entrectinib.  Entrectinib has shown preliminary antitumor activity in many different types of cancers.  Click here to learn more about a recent update from our Phase 1 study.

Please speak with your doctor to determine if molecular testing is right for you.  You may also contact Ignyta at 1.844.STARTRK or via email at STARTRKtrials@ignyta.com to learn more about the trial and to find a participating study center near you.

Interested in other studies?  Check out more information we’ve shared recently here.